HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data

HRD-MILN: Accurately estimate tumor homologous recombination deficiency status from targeted panel sequencing data

Homologous recombination deficiency (HRD) is a critical feature guiding drug and treatment selection, mainly for ovarian and breast cancers. As it cannot be directly observed, HRD status is estimated on a small set of genomic instability features from sequencing data. The existing methods often perf...

Full description

Bibliographic Details
Main Authors: Xuwen Wang, Ying Xu, Yinbin Zhang, Shenjie Wang, Xuanping Zhang, Xin Yi, Shuqun Zhang, Jiayin Wang
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Genetics
Subjects:
homologous recombination deficiency
targeted panel sequencing
multi-instance learning model
cancer genomics
sequencing data analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fgene.2022.990244/full

Internet

https://www.frontiersin.org/articles/10.3389/fgene.2022.990244/full

Similar Items